Bafna Pharmaceuticals Limited (IN:BAFNAPH)
:BAFNAPH
Want to see IN:BAFNAPH full AI Analyst Report?
Total Valuation
Bafna Pharmaceuticals Limited has a market cap or net worth of ₹3.93B. The enterprise value is ₹3.44B.
Market Cap₹3.93B
Enterprise Value₹3.44B
Share Statistics
Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,656,336
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bafna Pharmaceuticals Limited’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 7.16%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)7.16%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee4.15M
Profits Per Employee305.78K
Employee Count363
Asset Turnover0.86
Inventory Turnover4.51
Valuation Ratios
The current PE Ratio of Bafna Pharmaceuticals Limited is 35.3. Bafna Pharmaceuticals Limited’s PEG ratio is 0.14.
PE Ratio35.3
PS Ratio1.72
PB Ratio2.69
Price to Fair Value2.69
Price to FCF-19.79
Price to Operating Cash Flow42.10
PEG Ratio0.14
Income Statement
In the last 12 months, Bafna Pharmaceuticals Limited had revenue of 1.51B and earned 111.00M in profits. Earnings per share was 4.69.
Revenue1.51B
Gross Profit201.42M
Operating Income98.75M
Pretax Income109.70M
Net Income111.00M
EBITDA159.48M
Earnings Per Share (EPS)4.69
Cash Flow
In the last 12 months, operating cash flow was 93.13M and capital expenditures -164.17M, giving a free cash flow of -71.04M billion.
Operating Cash Flow93.13M
Free Cash Flow-71.04M
Free Cash Flow per Share-3.00
Dividends & Yields
Bafna Pharmaceuticals Limited pays an annual dividend of ₹0.6, resulting in a dividend yield of ―
Dividend Per Share₹0.6
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.62
52-Week Price Change118.75%
50-Day Moving Average139.56
200-Day Moving Average137.80
Relative Strength Index (RSI)57.82
Average Volume (3m)1.19K
Important Dates
Bafna Pharmaceuticals Limited upcoming earnings date is Aug 7, 2026, TBA (Confirmed).
Last Earnings DateMay 29, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
Bafna Pharmaceuticals Limited as a current ratio of 1.57, with Debt / Equity ratio of 38.93%
Current Ratio1.57
Quick Ratio1.06
Debt to Market Cap0.14
Net Debt to EBITDA2.22
Interest Coverage Ratio2.70
Taxes
In the past 12 months, Bafna Pharmaceuticals Limited has paid -1.30M in taxes.
Income Tax-1.30M
Effective Tax Rate-0.01
Enterprise Valuation
Bafna Pharmaceuticals Limited EV to EBITDA ratio is 18.45, with an EV/FCF ratio of -22.50.
EV to Sales1.95
EV to EBITDA18.45
EV to Free Cash Flow-22.50
EV to Operating Cash Flow24.87
Balance Sheet
Bafna Pharmaceuticals Limited has ₹19.67M in cash and marketable securities with ₹324.03M in debt, giving a net cash position of -₹304.36M billion.
Cash & Marketable Securities₹19.67M
Total Debt₹324.03M
Net Cash-₹304.36M
Net Cash Per Share-₹12.87
Tangible Book Value Per Share₹42.31
Margins
Gross margin is 22.65%, with operating margin of 6.56%, and net profit margin of 7.37%.
Gross Margin22.65%
Operating Margin6.56%
Pretax Margin7.28%
Net Profit Margin7.37%
EBITDA Margin10.59%
EBIT Margin6.56%
Analyst Forecast
The average price target for Bafna Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast3.26%
EPS Growth Forecast167.18%